Literature DB >> 3319498

Classification of cephalosporins.

J D Williams1.   

Abstract

Many cephalosporins are now in clinical use. They have a wide range of activity against different species of bacteria and also differ in their pharmacokinetic and metabolic characteristics. This article outlines a basis for comparison and classification of cephalosporins into 4 groups active mainly against: (1) Gram-positive bacteria; (2) Gram-negative rods; (3) Gram-negative rods including Pseudomonas spp.; and (4) Gram-negative rods including Bacteroides spp. Further subdivisions highlight the pharmacological differences.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319498     DOI: 10.2165/00003495-198700342-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  32 in total

1.  beta-Lactamases of subspecies of Bacteroides fragilis.

Authors:  T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

Review 2.  Cefoxitin, a semi-synthetic cephamycin: a microbiological overview.

Authors:  J Birnbaum; E O Stapley; A K Miller; H Wallick; D Hendlin; H B Woodruff
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

3.  Antibacterial activity of cefotaxime.

Authors:  S Mitsuhashi; M Inoue; S Masuyoshi
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

4.  beta-Lactamase stability of cefotaxime.

Authors:  M H Richmond
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

5.  Antimicrobial studies in vitro with CIBA 36278-Ba, a new cephalosporin derivative.

Authors:  F Knüsel; E A Konopka; J Gelzer; A Rosselet
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

6.  A comparative study of the activity of cefamandole and other cephalosporins and analysis of the beta-lactamase stability and synergy of cefamandole with aminoglycosides.

Authors:  K P Fu; H C Neu
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

7.  An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.

Authors:  B van Klingeren
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

8.  In vitro antibacterial activity and susceptibility of cefsulodin, an antipseudomonal cephalosporin, to beta-lactamases.

Authors:  A King; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

9.  Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191

10.  Cefoperazone concentrations in bile and gall bladder wall after intravenous administration.

Authors:  T Nakamura; I Hashimoto; Y Sawada; J Mikami; E Bekki; S Hirasawa; H Abe; Y Watanabe
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

View more
  10 in total

1.  Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.

Authors:  M D Reed; T S Yamashita; C K Knupp; J M Veazey; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Cephalosporin utilisation review and evaluation.

Authors:  G M Misan; C Dollman; D R Shaw; N Burgess
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 3.  Pharmacokinetic properties of the cephalosporins.

Authors:  T Bergan
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Drug utilization review of cephalosporins in a secondary care hospital in United Arab Emirates.

Authors:  Mohammad Abou-Shaaban; Areeg Anwer Ali; Padma G M Rao; Asif Majid
Journal:  Int J Clin Pharm       Date:  2016-11-05

Review 5.  Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.

Authors:  E Strehl; F Kees
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 6.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 7.  Cephalosporins--cefotaxime 10 years later, a major drug with continued use.

Authors:  H C Neu
Journal:  Infection       Date:  1991       Impact factor: 3.553

8.  Cefepime : The Last Generation or the First Enhanced-Potency Broad Spectrum Cephalosporin?

Authors:  C C Sanders; E S Moland
Journal:  Clin Drug Investig       Date:  1995-12       Impact factor: 2.859

Review 9.  Pharmacokinetics of cephalosporins in the neonate: a review.

Authors:  Gian Maria Pacifici
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

10.  Biochemical and Haematological Predictors of Reduced Neutrophil Granulocyte Count associated with Intravenous Ceftriaxone Treatment.

Authors:  Basant K Puri; Anne Derham; Jean A Monro
Journal:  Rev Recent Clin Trials       Date:  2018
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.